Search Results

The FDA is looking for stronger overall survival data to back Actinium’s application for Iomab-B, an investigational therapy that will allow acute myeloid leukemia patients to receive bone marrow transplants.

Actinium Pharmaceuticals, Inc. announced that it has launched a strategic initiative focused on the manufacture of the highly sought after medical isotope Actinium-225 leveraging its propriety cyclotron-based method.

Actinium Pharmaceuticals, Inc. announced that an abstract detailing the first ever preclinical data from the combination of menin inhibitors with Actinium’s ARC Actimab-A in acute myeloid leukemia models was presented at the 2024 European Hematology Association Congress held June 13 – 16, 2024, in Madrid, Spain.

Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of Antibody Radiation Conjugates (ARCs) and other targeted radiotherapies, today announced that results from the Phase 3 SIERRA trial of Iomab-B were presented at the 2024 European Hematology Association (EHA) Hybrid Congress being held June 13 – 16, 2024, in Madrid, Spain.

Actinium Pharmaceuticals, Inc. today announced it will host a KOL webinar on Monday, May 20, 2024, at 8:00 AM ET.

Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company) today highlighted data from the completed Phase 1b combination trial of Actimab-A + CLAG-M in patients with relapsed or refractory acute myeloid leukemia (r/r AML) at the 2024 Society of Nuclear Medicine & Molecular Imaging (SNMMI) Annual Meeting held June 8 – 11, 2024, in Toronto, Canada.

BWXT Medical Ltd. has submitted a Drug Master File to the U.S. Drug and Food Administration for No Carrier Added Actinium-225 Active Pharmaceutical Ingredient.

Actinium Pharmaceuticals, Inc. (NYSE AMERICAN: ATNM) (Actinium or the Company), a leader in the development of targeted radiotherapies, reported new analyses from the positive Phase 3 SIERRA trial of Iomab-B in oral presentations at the at the 2024 Tandem Meetings.

Actinium Pharmaceuticals, Inc., a leader in the development of Antibody Radiation Conjugates and other targeted radiotherapies, highlighted data from multiple abstracts that were presented at the 2024 Society of Nuclear Medicine & Molecular Imaging Annual Meeting being held June 8 – 11, 2024, in Toronto, Canada.

Actinium Pharmaceuticals, Inc. announced that five abstracts have been accepted for presentation at the 2024 Society of Nuclear Medicine & Molecular Imaging Annual Meeting being held June 8 – 11, 2024, in Toronto, Canada.